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Circulating tumours cells (CTCs) represent an important biologic link in the spread of breast cancer from primary to metastatic
disease. CTCs are strong predictors of prognosis in patients with metastatic breast cancer. Research to date has focused on
development of methods with adequate sensitivity and specificity to reproducibly identify these rare events. Future research will focus
on the biologic phenotypes of these cells with goals to understand mechanisms of metastasis, to identify novel therapeutic targets,
and to monitor response to therapy.
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The detection of circulating tumour cells (CTCs) in peripheral
blood has been of interest for over a century (Ashworth, 1869). The
existence of these cells fits nicely with the model of haematogenous
spread in the development of metastatic disease and has the
promise of providing a better understanding of the biology of
metastasis. Current assays available to the practicing breast
oncologist are largely based upon the presence or absence of
these cells, but in the future it is hoped that biologic characteristics
of CTCs, such as protein or mRNA expression, will be used in risk
assessment, tailoring of treatment, monitoring of response, and
development of novel therapeutic agents for patients with breast
cancer. For the purpose of this review, we will limit our discussion
to identification of circulating epithelial tumour cells in peripheral
blood from patients with breast cancer.
METHODS OF DETECTION
Much of the research over the past decade has focused on
development of methods with sufficient sensitivity and specificity
to detect CTCs, which are rare events occurring at a frequency of
approximately one tumour cell per 1 10
5 7 peripheral blood
mononuclear cells (Ross et al, 1993). Methods to identify CTCs
must distinguish between epithelial and haematopoietic cells in
blood. Secondarily, it may be desirable, although not necessarily
essential, to distinguish between cancer and normal epithelial cells.
Selection based upon physical properties such as morphology, size,
and weight have limitations in both sensitivity and specificity. In
the 1950–1960s, identification relied upon morphology using light
microscopy (Engell, 1959), but many of the identified cells are
believed to be false positives due to artifacts of preparation and by
the misclassification of leukocyte precursors (Christopherson,
1965). Cell separation by weight, as accomplished by the use of
ficoll gradient, is associated with a significant loss in CTCs, with a
recovery of only 10–65% cultured tumour cells spiked into whole
blood (Choesmel et al, 2004; Rolle et al, 2005). In comparison,
immunomagnetic separation techniques have approximately 85%
recovery (Witzig et al, 2002; Allard et al, 2004).
With the advent of antibody and nucleic acid technologies,
investigators turned to biologic properties such as protein
expression and mRNA expression to identify CTCs in whole
blood. Immunohistochemistry, immunofluorescent microscopy,
and flow cytometry techniques have allowed significant progress in
CTC research, but each of these in isolation continues to have both
biological and technical limitations. Many of the antibodies
directed at epithelial and breast cancer eptitopes are known to
also stain haematopoietic cells, including EpCAM (Choesmel et al,
2004), cytokeratins (Racila et al, 1998), MUC-1 (Brugger et al,
1999), and TAG-12 (Ahr et al, 1999). Some of these false positives
are concentration-dependent, and can be minimised by reducing
the antibody concentration (Ahr et al, 1999). Nonspecific
immunohistochemical staining of plasma cells can also occur
due to nonspecific alkaline phosphatase reactions against the
kappa and lambda light chains on the cell surface (Borgen et al,
1998). False positive rates range from 22 to 61% and vary based
upon the antibody and the staining methodology. Several changes
including optimisation of antibody concentration, selection of
more specific antibodies and the use of directly labeled fluorescent
monoclonal antibodies have improved some of these issues.
CTCs have also been indirectly identified using methods such as
RT-PCR and PCR. RT-PCR has been used to detect breast cancer
or epithelial associated mRNA transcripts such as cytokeratins,
EGFR, mammoglobin, MUC-1, beta-HCG, c-Met, GalNac-T,
MAGE-3, and others (Ring et al, 2004). However, as with
immunological strategies, RT-PCR has also been hampered by
false positives results in samples from normal volunteers and from
patients with haematologic malignancies (Ring et al, 2004). These
false positives stem from multiple sources, including issues with
laboratory technique, primer selection, and illegitimate expression
of the target genes in leukocytes. Interestingly, cytokeratin 19 and
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growth factors (Jung et al, 1998; Goeminne et al, 1999). RT-PCR
has also had problems with variable sensitivity. To increase
sensitivity, some investigators are now testing strategies in which
CTCs are identified by the presence of at least one mRNA
transcript out of a panel of two or more tumour-associated
transcripts (Taback et al, 2001; Ring et al, 2005). PCR has been
used to detect free DNA within plasma. However, PCR has also had
difficulty with poor specificity. This is due in part to the longer
half-life of DNA in plasma when compared to mRNA. As a result it
is unclear whether the free DNA that is amplified from plasma is
from CTCs in the circulation or if the DNA is being shed from
primary tumours, metastatic tumours, or from normal tissue (Ring
et al, 2004). Concerns over assay specificity with PCR may be
overcome by the identification of tumour specific DNA modifica-
tions, such as with methylation-specific PCR primers (Fiegl
et al, 2005). However, this does not resolve the question of the
origin of the amplified DNA. RT-PCR and PCR continue to have
methodologic hurdles to overcome, but they hold promise in the
effort to increase the sensitivity and specificity of CTC detection.
Published reports for the variety of CTC detction systems focus
primarily on sensitivity, specificity, and correlation with stage.
These reports vary dramatically in methodology, including the
methods and targets used for CTC isolation and visualisation,
definition of positive samples, and cohort size. They also vary in
the amount and type of data presented, and as a result the ability to
directly compare studies is limited. Specificity in many of these
studies is low due to selection of a low threshold of positivity (one
or more CTC). The most recent reports have used higher
thresholds, which result in improved specificity with only mild
losses in sensitivity (Cristofanilli et al, 2004; Ring et al, 2005).
The major finding of these studies is that the number of positive
patients and the absolute numbers of CTCs per patient rise as
clinical stage rises. The sensitivity in early stage disease continues
to be low, resulting in CTC numbers that are not significantly
different from those seen in control patients (Almokadem et al,
2005). This observation has limited the clinical use of CTCs to the
metastatic setting in which CTCs can be reproducibly found in at
least 50% of patients with metastatic breast cancer (Racila et al,
1998). Witzig et al (2002) purified CTC using immunomagnetic
isolation against EpCAM and immunofluorescence against cyto-
keratin in 14–20ml of blood. They identified X2 CTCs in 64% of
patient samples and X5 CTCs in 52% of patient samples. In all,
76% of metastatic breast cancer patients had a least one detectable
CTC and 8% of patients with node positive disease had at least one
detectable CTC. None of the patients with node negative breast
cancer had CTCs. None of the normal control samples had CTCs.
Cristofanilli et al (2004) isolated CTCs using immunomagnetic
isolation against EpCAM and immunofluorescence against cyto-
keratin in 7.5ml of blood from patients with metastatic disease.
They identified X2 CTCs in 61% of pretreatment patient samples,
and X5 CTCs in 49% of pretreatment samples. None of the normal
control samples had 42 CTCs, 1% had 2 CTCs, and 7% had 1 CTC.
Progress is now being made through the use of combined
methods. An example is the CellSearcht assay (Immunicon Corp.,
Hungtinton Valley, PA, USA), which is the only CTC assay to
receive FDA clearance. This system combines biologic isolation
techniques with biologic detection techniques, and uses an
automated system to decrease intersample variability. CTCs are
partially purified by immunomagnetic separation based upon
expression of either EpCAM. Other investigators have used
immunomagnetic separation based upon cytokeratin expression
(Hu et al, 2003). The CellSearch system then visualises the CTCs by
immunofluorescent microscopy. Other investigators have utilised
immunohistochemistry, flow cytometry or RT-PCR as the method
of detection and quantification after immunomagnetic isolation
(de Cremoux et al, 2000; Ring et al, 2004). Many systems, including
CellSearch, now routinely exclude non-specifically stained leuko-
cytes via use of antibody stains directed against leukocyte-specific
antigens such as CD45. Reproducibility has also been increased
through the used of automated sample preparation and automated
microscopy. The CellSearch system has been shown to be highly
accurate and reproducible (Allard et al, 2004). Blood samples
spiked with standardised numbers of cultured human breast
cancer cells demonstrate a linear recovery over a range of 5–1142
cells (correlation coefficient R
2¼0.99), with an average recovery of
485% at each level. There was also strong agreement between
duplicate samples (correlation coefficient R
2¼0.975) and between
independent operators reviewing the same digital images (correla-
tion coefficient R
2¼0.994).
CLINICAL UTILITY OF CTCs
There are many potential clinical applications for CTCs in breast
cancer including screening, predicting which patients with early
stage disease will recur despite adjuvant therapy, monitoring for
recurrence after adjuvant therapy, estimating prognosis in
metastatic disease, predicting which drug is most likely to be
efficacious for metastatic disease, and monitoring therapy for
metastatic disease. However, good data only exist for establishing
prognosis in metastatic breast cancer, and there is preliminary
data for monitoring therapy in metastatic breast cancer. Only two
studies have correlated the presence of immunopurified CTCs with
clinical outcome.
Gaforio et al (2003) evaluated a heterogeneous population of
patients spanning the clinical contexts of neoadjuvant therapy,
adjuvant therapy, and metastatic disease. Utilising Kaplan/Meier
PFS and OS curves, they found that patients with elevated CTCs
prior to therapy had worse PFS (P¼0.058) and OS (P¼0.003).
However, they did not stratify for disease stage, making inter-
pretation of the data difficult. In addition, at the time of publi-
cation neither of the medians for PFS or OS had been reached.
Similarly, but in a much more rigorous fashion, Cristofanilli
et al (2004, 2005) demonstrated that CTCs are highly prognostic in
the metastatic setting . In a prospective, double-blind, multi-centre
trial, 177 patients with metastatic breast cancer who were
beginning a new therapy were evaluated. The trial utilised
independent training and validation sets. Based upon the training
set, elevated CTCs were defined as X5 CTC per 7.5ml of whole
blood. Elevated CTCs at baseline predicted extremely short median
PFS and OS of 3 months and 10 months, respectively. This is in
comparison to patients with low/negative CTCs in whom PFS and
OS were 7 months and 22 months, respectively (Figure 1). Thus
baseline CTCs identify a group of high-risk patients. Even more
interesting, CTC values obtained after one cycle of therapy
predicted which patients were likely on ineffective therapy.
Patients with elevated CTCs after one cycle of therapy had median
PFS and OS of approximately 2.1 months and 8.2 months,
respectively when measured from baseline (Figure 1). In contrast,
median PFS and OS of 7.0 months and 22 months, respectively,
were observed in the group with low CTCs. These differences
were highly statistically significant (Po0.001) for patients receiv-
ing chemotherapy but not for patients receiving hormonal
therapies.
Approximately 50% of patients with metastatic breast cancer do
not have easily measurable disease. Therefore, the same investi-
gators conducted a continuation study of 46 patients with bone-
only disease, and CTCs were found to have similar prognostic
significance (Budd et al, 2005). Patients with elevated baseline
CTCs experienced a median PFS of 4.4 months and OS of 19
months compared to 9.5 (P¼0.44) and 420 (P¼0.25) months,
respectively, in patients with low CTCs. At first follow-up median
PFS were 3.5 and 14.4 months in the high- and low-risk groups,
respectively (P¼0.032). The medians for the OS endpoints have
not yet been reached.
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related phenomenon of micrometastatic disease in bone marrow
has also been demonstrated to be a strong prognostic factor when
evaluated at the time of definitive surgical therapy in early stage
breast cancer (Braun et al, 2000, 2005). The number of epithelial
cells in the bone marrow appears to be higher than in the peripheral
blood, increasing the sensitivity of the assay in early stage breast
cancer. As a result, such an assay may be useful in the risk
assessment and treatment decision-making in the adjuvant setting.
CURRENT CLINICAL STATUS OF CTCs
The recent study by Cristofanilli and colleagues strongly suggests
CTCs could aid in the evaluation and monitoring of patients with
metastatic breast cancer. The CellSearch assay has been cleared by
the FDA and is commercially available for establishing prognosis
in patients with metastatic disease. Current data appear to apply to
patients with metastatic breast cancer initiating chemotherapy but
not hormonal therapy. In selected patients, the prognostic value of
CTCs may be helpful in determining the aggressiveness of therapy.
CTC enumeration may be most helpful in selected patients with
nonmeasurable disease since the onset of progression is particu-
larly hard to determine in these patients. For patients in whom the
radiographic and clinical information is inconclusive, the prog-
nostic value of CTCs may allow a clinician to make a more
informed decision about whether currently therapy is working and
whether to switch therapies.
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Figure 2 Quantification of HER-2 density on cell lines and on CECs of
three breast cancer patients by flow cytometry. (A) HER-2 expression of
leukocytes, PC3 cells and SKBR-3 cells immunomagnetically selected from
5ml of blood and gated on size, CD45 expression, and cytokeratin
expression. The expression levels of HER-2 were subdivided into four
categories ( , þ, þþ, þþþ), based on the quantitative assessment
of HER-2 expression on PC3 and SKBR-3 cells. ( ) designates no
expression or less than 5000 receptors (WBC); (þ) designates expression
between 5000 and 50000 receptors (PC-3); (þþ) designates expression
between 50000 and 500000 receptors; and (þþþ) designates
expression of more than 500000 receptors (SKBR-3). (B–D) show the
expression of cytokeratin and HER-2 on CECs from three patients with
breast cancer. Only the CECs are shown in the panels. Reproduced with
permission from (Hayes et al, 2002).
Figure 1 Kaplan–Meier curves demonstrating differences in PFS (A and
C) and OS (B and D) based upon high and low risk CTC classifications.
Patients with elevated CTCs at baseline (A and B) and at first follow-up
after one cycle of therapy (C and D) have significantly worse median PFS
and OS compared to the corresponding patients with low CTCs. Adapted
with permission from (Cristofanilli et al, 2004).
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In follow-up of the Cristofanilli data, a prospective randomised
clinical trial has been developed in the Southwest Oncology Group
(SWOG S0500) to test whether women with metastatic breast
cancer and elevated CTCs at first follow-up after starting first line
chemotherapy benefit from switching early to an alternate therapy
compared to waiting for signs of clinical progression.
In addition to enumeration, an exciting area of CTC research
involves the phenotyping and expression profiling of CTCs. In this
regard, one might consider evaluation of CTCs as a real-time
biopsy. For most patients with metastatic breast cancer, the disease
is internal, making it technically difficult and often risky and
morbid to perform one biopsy, much less serial biopsies. It is
possible that serial evaluation of CTCs, requiring only a simple
blood test, may permit monitoring of drug targets during
treatment. Furthermore, a better understanding CTC biology is
likely to reveal previously unavailable information about the
mechanisms of metastasis. For example, genetic changes can be
detected in CTCs, including abnormal telomerase activity (Soria
et al, 1999), allelic loss and/or amplification of multiple oncogenes
not seen in normal control populations (Austrup et al, 2000), and
aneuploid changes in cellular chromosome content based upon
FISH analysis similar to those seen in the primary tumour (Fehm
et al, 2002). Additionally, cancer-associated protein expression
by CTCs can be detected, such as HER2 (Figure 2) (Hayes et al,
2002). Interestingly this report also suggests an inverse relation-
ship between the level of HER2 expression and the expression of
cytokeratin. Investigators have also demonstrated early successes
in gene expression profiling (Smirnov et al, 2005) and multiplex
RT-PCR (O’Hara et al, 2004) from CTCs. As each of these
methodologies becomes more sophisticated, our ability to isolate,
detect, and phenotype these cells will continue to improve.
If CTCs are placed in the broader concept of micrometastatic or
minimal residual disease, it is interesting to note that not all
patients with isolated tumour cells in regional lymph nodes,
peripheral blood, or bone marrow demonstrate recurrence of
their breast cancer. There are many possible explanations for
this observation. Given the methodological limitations, many of
these cells may simply be false positive events. However, the
absence of elevated CTCs in normal populations and the presence
of cytological abnormalities suggest otherwise. Thus some CTCs
may be clinically significant while others may be biologically
irrelevant. In other words, CTCs may differ in their proliferative
and metastatic potential. This is consistent with the growing
hypothesis of tumour stem cells (Al-Hajj et al, 2003; Dontu et al,
2004). If this hypothesis is true, then many micrometastatic cells,
including CTCs may not be capable of continual self-renewal. This
suggests that current therapies are targeting the ‘differentiated’
cells rather than the cancer stem cell. Work is ongoing to try to
identify circulating tumour stem cells.
CONCLUSIONS
CTCs undoubtedly play an important role in the development of
distant metastases in breast cancer as well as other solid tumours.
As a result of the rarity of these cells, our understanding of their
biology remains in its infancy. However, many new techniques for
the isolation and detection have been developed over the past
decade, and CTCs are now known to be a strong prognostic factor
in metastatic breast cancer. Investigators continue to develop more
sophisticated methods to phenotype CTCs. This should lead to the
discovery of new therapeutic targets as well as the ability to
monitor the modulation of these targets during clinical trials and
eventually as a part of standard of care therapy.
ACKNOWLEDGEMENTS
This work was supported by Fashion Footwear Association of New
York/QVC Presents ‘FFANY Shoes on Sale’ (to DF Hayes).
REFERENCES
Ahr A, Scharl A, Muller M, von Minckwitz G, Gatje R, Pantel K, Kaufmann
M (1999) Cross-reactive staining of normal bone-marrow cells by
monoclonal antibody 2E11. Int J Cancer 84: 502–505
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003)
Prospective identification of tumorigenic breast cancer cells. Proc Natl
Acad Sci USA 100: 3983–3988
Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG,
Uhr JW, Terstappen LW (2004) Tumor cells circulate in the peripheral
blood of all major carcinomas but not in healthy subjects or patients with
nonmalignant diseases. Clin Cancer Res 10: 6897–6904
Almokadem S, Leitzel K, Harvey HA, Bannon E, Ali S, Miller C, Repollet M,
Allard J, Terstappen LW, Lipton A (2005) Circulating tumor cells in
adjuvant breast cancer patients. J Clin Oncol 23: 667
Ashworth TR (1869) A case of cancer in which cells similar to those in the
tumours were seen in the blood after death. Aus Med J 14: 146–149
Austrup F, Uciechowski P, Eder C, Bockmann B, Suchy B, Driesel G, Jackel
S, Kusiak I, Grill HJ, Giesing M (2000) Prognostic value of genomic
alterations in minimal residual cancer cells purified from the blood of
breast cancer patients. Br J Cancer 83: 1664–1673
Borgen E, Beiske K, Trachsel S, Nesland JM, Kvalheim G, Herstad TK,
Schlichting E, Qvist H, Naume B (1998) Immunocytochemical detection
of isolated epithelial cells in bone marrow: non-specific staining and
contribution by plasma cells directly reactive to alkaline phosphatase.
J Pathol 185: 427–434
Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S,
Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G (2000)
Cytokeratin-positive cells in the bone marrow and survival of patients
with stage I, II, or III breast cancer. N Engl J Med 342: 525–533
Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok
G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D,
Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY,
Bliss J, Vincent-Salomon A, Pantel K (2005) A pooled analysis of
bone marrow micrometastasis in breast cancer. N Engl J Med 353:
793–802
Brugger W, Buhring HJ, Grunebach F, Vogel W, Kaul S, Muller R,
Brummendorf TH, Ziegler BL, Rappold I, Brossart P, Scheding S, Kanz L
(1999) Expression of MUC-1 epitopes on normal bone marrow:
implications for the detection of micrometastatic tumor cells. J Clin
Oncol 17: 1535–1544
Budd GT, Cristofanilli M, Ellis M, Stopeck A, Matera J, Miller MC, Doyle G,
Allard J, Terstappen LW, Hayes D (2005) Monitoring circulating tumor
cells (CTC) in non measurable metastatic breast cancer (MBC). J Clin
Oncol 23: 503
Choesmel V, Pierga JY, Nos C, Vincent-Salomon A, Sigal-Zafrani B, Thiery
JP, Blin N (2004) Enrichment methods to detect bone marrow
micrometastases in breast carcinoma patients: clinical relevance. Breast
Cancer Res 6: R556–R570
Christopherson WM (1965) Cancer cells in the peripheral blood: A second
look. Acta Cytologica 9: 169–174
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Doyle
GV, Allard WJ, Terstappen LW, Hayes DF (2005) Presence of circulating
tumor cells (CTC) in metastatic breast cancer (MBC) predicts rapid
progression and poor prognosis. J Clin Oncol 23: 524
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben
JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating
tumor cells, disease progression, and survival in metastatic breast cancer.
N Engl J Med 351: 781–791
de Cremoux P, Extra JM, Denis MG, Pierga JY, Bourstyn E, Nos C, Clough
KB, Boudou E, Martin EC, Muller A, Pouillart P, Magdelenat H (2000)
Detection of MUC1-expressing mammary carcinoma cells in the
Circulating tumour cells in breast cancer
JB Smerage and DF Hayes
11
British Journal of Cancer (2006) 94(1), 8–12 & 2006 Cancer Research UKperipheral blood of breast cancer patients by real-time polymerase chain
reaction. Clin Cancer Res 6: 3117–3122
Dontu G, El-Ashry D, Wicha MS (2004) Breast cancer, stem/progenitor cells
and the estrogen receptor. Trends Endocrinol Metab 15: 193–197
Engell HC (1959) Cancer cells in the blood; a five to nine year follow up
study. Ann Surg 149: 457–461
Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D, Meng
S, Morrison L, Tucker T, Lane N, Ghadimi BM, Heselmeyer-Haddad K,
Ried T, Rao C, Uhr J (2002) Cytogenetic evidence that circulating
epithelial cells in patients with carcinoma are malignant. Clin Cancer Res
8: 2073–2084
Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A,
Klocker H, Goebel G, Widschwendter M (2005) Circulating tumor-
specific DNA: a marker for monitoring efficacy of adjuvant therapy in
cancer patients. Cancer Res 65: 1141–1145
Gaforio JJ, Serrano MJ, Sanchez-Rovira P, Sirvent A, Delgado-Rodriguez M,
Campos M, de la Torre N, Algarra I, Duenas R, Lozano A (2003)
Detection of breast cancer cells in the peripheral blood is positively
correlated with estrogen-receptor status and predicts for poor prognosis.
Int J Cancer 107: 984–990
Goeminne JC, Guillaume T, Salmon M, Machiels JP, D’Hondt V, Symann M
(1999) Unreliability of carcinoembryonic antigen (CEA) reverse tran-
scriptase-polymerase chain reaction (RT-PCR) in detecting contaminat-
ing breast cancer cells in peripheral blood stem cells due to induction of
CEA by growth factors. Bone Marrow Transplant 24: 769–775
Hayes DF, Walker TM, Singh B, Vitetta ES, Uhr JW, Gross S, Rao C,
Doyle GV, Terstappen LW (2002) Monitoring expression of HER-2 on
circulating epithelial cells in patients with advanced breast cancer. Int J
Oncol 21: 1111–1117
Hu XC, Wang Y, Shi DR, Loo TY, Chow LW (2003) Immunomagnetic
tumor cell enrichment is promising in detecting circulating breast cancer
cells. Oncology 64: 160–165
Jung R, Kruger W, Hosch S, Holweg M, Kroger N, Gutensohn K, Wagener
C, Neumaier M, Zander AR (1998) Specificity of reverse transcriptase
polymerase chain reaction assays designed for the detection of
circulating cancer cells is influenced by cytokines in vivo and in vitro.
Br J Cancer 78: 1194–1198
O’Hara SM, Moreno JG, Zweitzig DR, Gross S, Gomella LG, Terstappen LW
(2004) Multigene reverse transcription-PCR profiling of circulating
tumor cells in hormone-refractory prostate cancer. Clin Chem 50:
826–835
Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW
(1998) Detection and characterization of carcinoma cells in the blood.
Proc Natl Acad Sci USA 95: 4589–4594
Ring A, Smith IE, Dowsett M (2004) Circulating tumour cells in breast
cancer. Lancet Oncol 5: 79–88
Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M (2005) Detection of
circulating epithelial cells in the blood of patients with breast cancer:
comparison of three techniques. Br J Cancer 92: 906–912
Rolle A, Gunzel R, Pachmann U, Willen B, Hoffken K, Pachmann K
(2005) Increase in number of circulating disseminated epithelial cells
after surgery for non-small cell lung cancer monitored by MAIN-
TRAC(R) is a predictor for relapse: A preliminary report. World J Surg
Oncol 3: 18
Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N,
Tallman MS, Kennedy MJ, Davidson NE, Sweet D, Winter C,
Akard L, Jansen J, Copelan E, Meagher RC, Herzing RH, Klumpp TR,
Kahn DG, Warner NE (1993) Detection and viability of tumor cells
in peripheral blood stem cell collections from breast cancer patients
using immunocytochemical and clonogenic assay techniques. Blood 82:
2605–2610
Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pienta KJ,
Meropol NJ, Weiner LM, Cohen SJ, Moreno JG, Connelly MC, Terstappen
LW, O’Hara SM (2005) Global gene expression profiling of circulating
tumor cells. Cancer Res 65: 4993–4997
Soria JC, Gauthier LR, Raymond E, Granotier C, Morat L, Armand JP,
Boussin FD, Sabatier L (1999) Molecular detection of telomerase-positive
circulating epithelial cells in metastatic breast cancer patients. Clin
Cancer Res 5: 971–975
Taback B, Chan AD, Kuo CT, Bostick PJ, Wang HJ, Giuliano AE, Hoon DS
(2001) Detection of occult metastatic breast cancer cells in blood by a
multimolecular marker assay: correlation with clinical stage of disease.
Cancer Res 61: 8845–8850
Witzig TE, Bossy B, Kimlinger T, Roche PC, Ingle JN, Grant C, Donohue J,
Suman VJ, Harrington D, Torre-Bueno J, Bauer KD (2002) Detection of
circulating cytokeratin-positive cells in the blood of breast cancer
patients using immunomagnetic enrichment and digital microscopy. Clin
Cancer Res 8: 1085–1091
Circulating tumour cells in breast cancer
JB Smerage and DF Hayes
12
British Journal of Cancer (2006) 94(1), 8–12 & 2006 Cancer Research UK